Press Releases

All Releases
AngioDynamics to Present at Two Investor Conferences in May
Apr 10, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will present at the following two investor conferences in May:
AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
Mar 29, 2018
Fiscal 2018 Third Quarter Highlights Net sales of $83.9 million , a decrease of 2.0% year over year Gross margin expanded 300 basis points year over year to 54.2% GAAP EPS of $0.37 ; Adjusted EPS of $0.25 per share Announced the launch of a wireless ultrasound device FDA granted Breakthrough
AngioDynamics to Present at the Needham 17th Annual Healthcare Conference
Mar 15, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Michael C. Greiner, Executive Vice President and Chief Financial
AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March 29, 2018
Feb 27, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the third quarter of fiscal
AngioDynamics to Present at the Barclays Global Healthcare Conference
Feb 15, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and Michael C.
AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer
Jan 24, 2018
LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration (FDA) has granted
AngioDynamics Reports Fiscal 2018 Second Quarter Financial Results
Jan 04, 2018
Fiscal 2018 Second Quarter Highlights Net sales of $86.7 million , a decrease of 2.6% year over year U.S. GAAP EPS of $0.01 ; Adjusted EPS of $0.16 per share Operating cash flow of $10.2 million ; free cash flow of $9.4 million LATHAM, N.Y. --(BUSINESS WIRE)-- AngioDynamics , Inc. (NASDAQ:ANGO), a
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
Dec 19, 2017
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 19, 2017-- AngioDynamics , Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that Jim Clemmer , President and Chief Executive Officer,
AngioDynamics to Report Fiscal 2018 Second Quarter Financial Results on January 4, 2018
Dec 11, 2017
LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 11, 2017-- AngioDynamics , Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that it will report financial results for the second
AngioDynamics Reports Fiscal 2018 First Quarter Results
Sep 28, 2017
Q1 net sales of $85.4 million , down 3% year-over-year              Q1 GAAP earnings per share of $0.00 ; adjusted EPS of $0.12 Q1 operating cash generation of $3.0 million ; free cash flow generation of $2.5 million Company reaffirms fiscal 2018 guidance ALBANY, N.Y. , Sept.
Outcomes in a Nurse-Led Peripherally Inserted Central Catheter Program: A Retrospective Cohort Study Published in CMAJ Open
Sep 14, 2017
Low rates of major PICC-associated complications attributed in-part to the novel BioFlo catheter material Data to be presented at AngioDynamics -sponsored symposium at the annual scientific meeting of the Association for Vascular Access ALBANY, N.Y. , Sept.
AngioDynamics to Report Fiscal 2018 First Quarter Financial Results
Sep 14, 2017
ALBANY, N.Y. , Sept. 14, 2017 (GLOBE NEWSWIRE) -- AngioDynamics  (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2018 first
AngioDynamics to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
Sep 13, 2017
ALBANY, N.Y. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael C.
AngioDynamics to Present at the 2017 Morgan Stanley Global Healthcare Conference
Aug 29, 2017
ALBANY, N.Y. , Aug. 29, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Jim Clemmer , President and Chief Executive Officer and
AngioDynamics to Present at the 2017 Canaccord Genuity Growth Conference
Aug 07, 2017
ALBANY, N.Y. , Aug. 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael Greiner , Executive Vice President and Chief
AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
Jul 18, 2017
Company posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance Q4 net sales of $86.9 million , down 7% year-over-year Q4 GAAP loss per share of $0.30 ; adjusted EPS of $0.19 Full Year net sales of $349.6 million , down 1% year-over-year Full Year GAAP earnings
AngioDynamics to Report Fiscal 2017 Fourth Quarter and Full-Year Financial Results
Jul 07, 2017
ALBANY, N.Y. , July 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2017 fourth
AngioDynamics Announces FDA Clearance for The Solero Microwave Tissue Ablation System
Jun 07, 2017
ALBANY, N.Y. , June 07, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology/surgery, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k)
AngioDynamics Lawsuit Alleges C.R. Bard is Violating Antitrust Laws, Harming Competition and Limiting Access
May 31, 2017
ALBANY, N.Y. , May 31, 2017 (GLOBE NEWSWIRE) -- C.R. Bard has illegally tied the sale of its tip location systems to its line of peripherally inserted central catheters ("PICCs"), violating federal antitrust laws, preventing competition in the marketplace and limiting patient access to superior
AngioDynamics to Present at the 2017 UBS Global Healthcare Conference
May 09, 2017
ALBANY, N.Y. , May 09, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Michael C. Greiner , Executive Vice President and Chief
Displaying 1 - 20 of 615

Copyright Nasdaq. Minimum 15 minutes delayed.